Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 18.64
BBH's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 18.64 )
Ranked among companies with meaningful P/E(ttm) only.
BBH' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 19.39
Current: 18.64
0
19.39
PE(NRI) 18.64
BBH's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 18.64 )
Ranked among companies with meaningful PE(NRI) only.
BBH' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 19.39
Current: 18.64
0
19.39
P/B 6.63
BBH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 6.63 )
Ranked among companies with meaningful P/B only.
BBH' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.9
Current: 6.63
0
6.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.28
BBH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 0.28 )
Ranked among companies with meaningful Dividend Yield only.
BBH' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.28
Current: 0.28
0
0.28
Yield on cost (5-Year) 0.28
BBH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 0.28 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BBH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.28
Current: 0.28
0
0.28

More Statistics

Short Percentage of Float0.00%
52-Week Range $95.56 - 134.00
Shares Outstanding (Mil)5,296,503.00
» More Articles for BBH

Headlines

Articles On GuruFocus.com
There’s More Than One Way to Find a Great Stock Aug 25 2016 
Warren Buffett Adds to Phillips 66 Aug 25 2016 
Financial Metrics on Industries Provide Investing Insights Aug 25 2016 
2 More Reasons Why Buffett Continues to Buy Phillips 66 Aug 25 2016 
Bill Nygren Gains 1, Loses 1 in 2nd Quarter Aug 25 2016 
The 3 Worst Performing Dividend Aristocrats This Year Aug 25 2016 
Jim Rogers Is 1 of the World's Best Investors Aug 25 2016 
US Equity Market Has More to Gain Aug 25 2016 
HP: A Bet on the Future of 3-D Printer Market? Aug 25 2016 
Brandes Funds Comments on Ericsson Aug 24 2016 

More From Other Websites
Pfizer’s Medivation Acquisition: What You Need to Know Aug 23 2016
Ozanimod May Prove to Be a Strong Growth Driver for Celgene Aug 18 2016
These Concerns Affected Gilead’s Change in Full-Year Guidance Aug 02 2016
Vertex’s Orkambi to Treat Cystic Fibrosis Drives Company’s Growth Aug 01 2016
BioMarin: Why So Many ‘Buy’ Recommendations? Jul 31 2016
Why Did Alnylam Pharmaceuticals’s Valuation Multiples Drop in 2016? Jul 08 2016
Understanding the Valuation Catalysts for BioMarin in 4Q16 Jul 06 2016
Hunting for value Jul 01 2016
Deutsche Balaton AG :BBH-DE: Earnings Analysis: For the six months ended December 31, 2015 : June... Jun 29 2016
Which Biotechnology Companies Could Benefit from Brexit? Jun 28 2016
As Cost Panel Gets Delayed, Buy These 3 Biotech ETFs Jun 23 2016
Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead May 17 2016
What Lies Ahead for Biotech ETFs? May 13 2016
Will the Current Pipeline Help Medivation Go beyond Xtandi? May 12 2016
The Story behind Medivation’s Rising Collaboration Revenue May 11 2016
A Promising Uptake for Vertex’s Orkambi May 04 2016
Biotech ETFs Sink on Mixed Q1 Results May 02 2016
2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap May 02 2016
Why Is Medivation at a Premium on an EV-to-EBITDA Basis? Apr 14 2016
A Rare Opportunity With A Biotechnology ETF Mar 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK